Also, it is trading at rather expensive levels at just over 1.02x price/book and 3.77x price/sales. TTNP’s ROE is -904.1%, which is also considerably worse than the industry’s ROE of 16.92%. It’s also very liquid in the near term, with a current ratio of 5.2. The stock has a debt/capital of 0.75.
TTNP’s 50 day simple moving average (SMA 50) price is $0.32 and its 200-day simple moving average (SMA 200) price is $0.75. The company’s stock currently has a total float of 74.61M shares. Its weekly volatility is hovering around 8.3% and felt 10.84% volatility in price over a month. On the upside, the share price will test short term resistance at around $0.27. On a downside, the stock is likely to find some support, which begins at $0.24. The failure to get near-term support could push it to $0.23.
Separately, it has been reported that multiple insider activity took place at Titan Pharmaceuticals, Inc. (TTNP). Executive Chairman Rubin Marc acquired 400,000 shares for $556,317 in transaction occurred on 2018/09/21. After making this transaction, the Executive Chairman owns a direct stake of 100,000 shares, worth $139,079, as per the last closing price. On 2018/09/21 Mcnab James R, Director at TTNP, purchased 200,000 shares at an average price of $0.25 per share. The new stake is valued at $75,000.
Bhonsle Sunil had invested in 300,000 shares for $490,262 through a trade on 2018/09/21. Following this activity, the insider holds 75,000 shares worth $122,566 as of recent close. Wall Street’s most bullish Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) analysts are predicting the share price to blow past $0.65 per share during the next 12 months. The current median share price forecast by them is $0.65, suggesting that the stock could increase 160% in that time frame. The average price target of $0.65 calls for a nearly 160% increase in the stock price.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) reached $20.34M by 06-December-18 in the wake of -13.39% downturn. The shares gained some momentum after bears carried it down to $0.25. The final price for the day of 0.25 was still down from $0.279. The stock remained range bound between $0.25 and $0.279. Trading activity significantly weakened as the volume at ready counter decreased to 4,917,839 shares versus 5,018,015 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 2,765,435 shares. The stock is now 47.06% above against its bear-market low of $0.17 on October 03, 2018. It has retreated -520% since it’s 52-week high of $1.55 reached in December. Now the market price is down -83.6% on the year and down -80.82% YTD.
Shares of Titan Pharmaceuticals, Inc. (TTNP) have dropped -38.3% since the company’s last earnings report. Over the past 12 fiscal quarters, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has topped consensus earnings estimates in 5 quarters (41%), missed earnings in 6 quarters (50%), whereas at 1 occasion EPS met analyst expectations. TTNP last reported earnings on November 14, 2018 when it released Sep-18 results that exceeded expectations. The company raked in -$0.11 per share, -99.49% change on the same period last year. That was better than consensus for -$0.14. Revenue for the recent quarter stood at $1.65 million, up 4025% on last year and above the $100000 predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $300000 to $300000, which should be compared with $0 generated last year. EPS is seen in a range of -$0.05 to -$0.05, against the 0 reported a year ago.